Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response

PURPOSE: Faecal incontinence (FI) is distressing, significantly reduces quality of life (QoL) and has few pharmacological treatments. The α(1)-adrenoceptor agonist NRL001 (1R,2S-methoxamine hydrochloride) improves anal sphincter tone. NRL001 efficacy was evaluated by changes in Wexner scores at week...

Descripción completa

Detalles Bibliográficos
Autores principales: Siproudhis, L., Graf, W., Emmanuel, A., Walker, D., Shing, R. Ng Kwet, Pediconi, C., Pilot, J., Wexner, S., Scholefield, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867152/
https://www.ncbi.nlm.nih.gov/pubmed/27075314
http://dx.doi.org/10.1007/s00384-016-2585-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867152/
https://www.ncbi.nlm.nih.gov/pubmed/27075314
http://dx.doi.org/10.1007/s00384-016-2585-7

Ejemplares similares